Genomic characterization of ESBL-producing Escherichia coli isolates from patients in an orthopaedic ward in Mwanza, Tanzania
F1000Research · 05.05.2026 · 15 · 670
DOI: 10.12688/f1000research.180294.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, online erschienen am 05.05.2026. Verfasst von Gerald Mboowa und 4 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grand Challenges Africa programme, Fogarty International Center of the National Institutes of Health.
Abstract (Originalsprache)
Background
Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli are a major contributor to antimicrobial resistance (AMR) in healthcare settings, yet their genomic diversity and population structure remain poorly characterized in low-resource settings. Orthopaedic wards may facilitate persistence and transmission due to prolonged hospitalization, frequent antimicrobial exposure, and increased patient vulnerability. This study investigated the genomic characteristics of ESBL-producing E. coli recovered from hospitalized patients in an orthopaedic ward in Mwanza, Tanzania.
Methods
We performed whole-genome sequencing and comparative genomic analysis of ESBL-confirmed E. coli isolates obtained from stool or rectal swabs of hospitalized patients. Sequence reads were quality controlled and assembled using standard pipelines. Core genome single nucleotide polymorphism (SNP) alignments were generated using Snippy, and recombination was identified and masked using Gubbins prior to phylogenetic reconstruction. Sequence types (STs), AMR determinants, plasmid replicons, and virulence-associated genes were identified using established bioinformatics tools and databases.
Results
Phylogenetic analysis revealed a polyclonal population structure comprising multiple distinct lineages rather than a single outbreak clone. Several isolates formed tight phylogenetic clusters within the ward, consistent with local circulation of closely related strains. The population included internationally recognized sequence types, including ST131, ST1193, ST69, ST617, and ST38. ESBL production was predominantly associated with bla CTX-M-15 , detected in most isolates, alongside additional resistance determinants to aminoglycosides, quinolones, sulfonamides, trimethoprim, and tetracyclines. IncF-family plasmid replicons predominated, with additional IncY plasmids identified. Virulence-associated genes, including fdeC and ybtP/ybtQ , were widely distributed.
Conclusions
ESBL-producing E. coli in this orthopaedic ward represent a genomically diverse, multidrug-resistant population dominated by bla CTX-M-15 -positive lineages. The coexistence of multiple lineages alongside closely related clusters suggests ongoing circulation of high-risk clones. These findings highlight colonized patients as reservoirs of AMR and underscore the need to integrate genomic surveillance into infection prevention and control strategies in resource-constrained healthcare settings.
Förderung
- Grand Challenges Africa programme
- Fogarty International Center of the National Institutes of Health
Zitieren
APA
Mboowa, G., Kidenya, B. R., Sserwadda, I., Kanyerezi, S., & Seni, J. (2026). Genomic characterization of ESBL-producing Escherichia coli isolates from patients in an orthopaedic ward in Mwanza, Tanzania. F1000Research, 15, 670. https://doi.org/10.12688/f1000research.180294.1
Vancouver
Mboowa G, Kidenya BR, Sserwadda I, Kanyerezi S, Seni J. Genomic characterization of ESBL-producing Escherichia coli isolates from patients in an orthopaedic ward in Mwanza, Tanzania. F1000Research. 2026;15:670. doi:10.12688/f1000research.180294.1
BibTeX
@article{Mboowa2026,
author = {Mboowa, Gerald and Kidenya, Benson R and Sserwadda, Ivan and Kanyerezi, Stephen and Seni, Jeremiah},
title = {Genomic characterization of ESBL-producing Escherichia coli isolates from patients in an orthopaedic ward in Mwanza, Tanzania},
journal = {F1000Research},
year = {2026},
volume = {15},
pages = {670},
doi = {10.12688/f1000research.180294.1}
}
EUVIMED